<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853475</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_13_002</org_study_id>
    <secondary_id>2013-000983-28</secondary_id>
    <nct_id>NCT01853475</nct_id>
  </id_info>
  <brief_title>Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State</brief_title>
  <official_title>Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS Formulation in the Fasted State in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Piperaquine tablets (coated) + OZ439 granules + TPGS granules will be co-administered in
      Phase IIb (adults). However, safety and PK data (for OZ439 plus piperaquine) were obtained
      using piperaquine tablets plus OZ439 as Powder in Bottle with milk. Piperaquine has not yet
      been administered together with TPGS. Co-administration of piperaquine plus OZ439 as Powder
      in Bottle (PIB) with milk results in an increase in OZ439 exposure (current estimate ~ 70%
      due to a small drug drug interaction).

      This study investigates the exposure of piperaquine and OZ439 when co-administered as
      piperaquine phosphate tablets and OZ439 + TPGS prototype (a formulation close to that of
      Phase IIb, but not identical), in order to select the appropriate doses for Phase IIb. The
      reference treatment is piperaquine phosphate tablets + OZ439 Powder in Bottle + full fat milk
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        1. To evaluate the piperaquine and OZ439 pharmacokinetics when administered as a
           combination of piperaquine phosphate tablets with OZ439 / TPGS formulation in the fasted
           state

        2. To evaluate the piperaquine and OZ439 pharmacokinetics of a reference free combination
           formulation: piperaquine phosphate tablets with OZ439 powder in bottle (PIB) given with
           full fat milk

        3. To determine safety and tolerability of OZ439 and piperaquine phosphate when
           co-administered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
    <description>OZ439 maximum concentration observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 AUC0-inf</measure>
    <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
    <description>Area under the OZ439 plasma concentration time curve from time zero to time infinity using observed values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Piperaquine Cmax</measure>
    <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
    <description>Piperaquine maximum concentration observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Piperaquine AUC0-inf</measure>
    <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
    <description>Area under the Piperaquine plasma concentration time curve from time zero to time infinity using observed values.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C - Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQP tablets 960mg</intervention_name>
    <description>Piperaquine phosphate tablets 960mg</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQP tablets 1440mg</intervention_name>
    <description>Piperaquine phosphate tablets 1440mg</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C - Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439+TPGS 800mg</intervention_name>
    <description>OZ439+TPGS prototype formulation 800mg</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 PIB 800mg</intervention_name>
    <description>OZ439 Powder in Bottle Aqueous Solution 800mg</description>
    <arm_group_label>Treatment C - Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male/female of any race aged 18-55 years at screening

          2. Body Mass Index 18-30kg/m2; body weight &gt;50kg but no more than 100kg at screening

          3. Females with negative pregnancy test at screening and admission, non-lactating and of
             non-child bearing potential confirmed

          4. Agree to use acceptable methods of contraception

          5. Should not donate egg and sperm from the time of administration of treatment or study
             medication until 3 months following dose of study medication

          6. Must be capable of understanding and complying with the requirements of the protocol
             and must have signed the informed consent form prior to undergoing any study-related
             procedures

        Exclusion Criteria:

          1. Male subjects with a female partner(s) who is (are) pregnant or lactating from the
             time of the administration of study medication

          2. Has a clinically significant disease or any condition or disease that might affect
             drug absorption, distribution or excretion, e.g. gastrectomy, diarrhoea.

          3. History of allergic reactions to artemisinin-based compounds, 4-aminoquinolines such
             as piperaquine or any other clinically relevant allergy to drugs or food.

          4. Any clinically relevant history of cow's milk intolerance/allergy.

          5. Any clinically significant abnormal laboratory, vital signs or other safety findings
             as determined by medical history, physical examination or other evaluations conducted
             at screening or on admission. Exception is PR, QTcB, QTcF, cardiac rhythm, liver
             function tests and haemoglobin that must be within the normal reference range at
             screening and on admission.

          6. History or current evidence of any clinically relevant cardiovascular, pulmonary,
             hepatic, renal, gastrointestinal (excluding appendectomy and cholecystectomy),
             haematological, endocrinological, immunological, metabolic, neurological, oncological,
             psychiatric, urological or other disease, or current infection

          7. History of post-antibiotic colitis

          8. Electrocardiogram abnormalities in the standard 12-lead (at screening) and/or 24-hour
             5 lead Holter (at screening) which in the opinion of the Investigator is clinically
             relevant or will interfere with the analysis

          9. A history of clinically significant electrocardiogram abnormalities, or any of the
             following abnormalities at screening or admission:

               -  PR &gt;200 msec

               -  QRS complex &gt;120 msec

               -  QTcB or QTcF &gt;450 msec or shortened QTcB or QTcF less than 340 msec for males and
                  females or family history of long QT syndrome or sudden death

               -  Any degree of heart block (such as first, second or third degree atrioventricular
                  block, incomplete, full or intermittent bundle branch block)

               -  Abnormal T wave morphology / prominent U waves

               -  Potassium levels out of the normal range at screening and prior to dosing

         10. Positive results in any of the serology tests for Hepatitis B Surface Antigen, anti
             Hepatitis core antibody, Hepatitis C antibodies, and Human Immunodeficiency Virus 1
             and 2 antibodies

         11. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,
             cocaine, cannabinoids, opiates, barbiturates, and methadone) or from the alcohol
             breath test at screening and admission

         12. History or clinical evidence of alcohol abuse, or any recreational drug abuse within
             the 2 years prior to screening

         13. Mentally handicapped

         14. Participation in a drug trial within 90 days prior to drug administration

         15. Use of ANY prescription or over the counter medications, within 3 weeks of study drug
             administration, or vitamins or herbal supplements within 2 week of administration of
             the drug administration of study drug (or at least 5 half-lives of the compound
             whichever period is the longer), unless prior approval is granted by both the
             Investigator and Sponsor. Excluded from this list is intermittent use of paracetamol
             at up to 2g/day.

         16. Use moderate or strong inhibitors and/or inducers of cytochrome CYP450 within 4 weeks
             prior to the planned drug administration (or at least 5 half-lives of the compound
             whichever period is the longer)

         17. Subjects have veins unsuitable for intravenous puncture or cannulation on either arm
             (e.g. veins that are difficult to locate, access or puncture veins with a tendency to
             rupture during or after puncture)

         18. Blood liver function tests not in the normal range at screening and on admission

         19. Haemoglobin is less than the lower limit of the reference range at screening and on
             admission.

         20. Donation of more than 500mL blood within 90 days prior to drug administration

         21. Subjects must be non-smokers for at least 3 months prior to screening Note: &quot;Tobacco
             use&quot; includes smoking and the use of snuff and chewing tobacco, and other nicotine or
             nicotine containing products

         22. Any consumption of grapefruit, Seville oranges, wild grapes, black mulberries,
             pomegranates in the form of fruit juice, marmalade or as a raw fruit within 7 days
             prior to dosing of study drug and throughout the study. Any circumstances or
             conditions, which, in the opinion of the investigator may affect full participation in
             the trial or compliance with the protocol

         23. Legal incapacity or limited legal capacity at screening

         24. Vegetarians, vegans or any dietary restrictions conflicting with the study
             standardised menus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Lorch, MD FRCA FFPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richmond Pharmacology Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richmond Pharmacology Limited</name>
      <address>
        <city>Croyden</city>
        <state>London</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <results_first_submitted>March 27, 2015</results_first_submitted>
  <results_first_submitted_qc>March 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2015</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piperaquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="P2">
          <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="P3">
          <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
          <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 24 subjects who had received at least one treatment of randomised study medication and for whom any post-treatment data was available.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="B2">
          <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="B3">
          <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
          <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="13.06"/>
                    <measurement group_id="B2" value="30.1" spread="6.33"/>
                    <measurement group_id="B3" value="30.1" spread="5.79"/>
                    <measurement group_id="B4" value="31.3" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 Cmax</title>
        <description>OZ439 maximum concentration observed</description>
        <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
        <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
            <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>OZ439 maximum concentration observed</description>
          <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1540" spread="26.0"/>
                    <measurement group_id="O2" value="1360" spread="33.8"/>
                    <measurement group_id="O3" value="1610" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC0-inf</title>
        <description>Area under the OZ439 plasma concentration time curve from time zero to time infinity using observed values.</description>
        <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
        <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
            <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-inf</title>
          <description>Area under the OZ439 plasma concentration time curve from time zero to time infinity using observed values.</description>
          <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17500" spread="27.9"/>
                    <measurement group_id="O2" value="16000" spread="24.7"/>
                    <measurement group_id="O3" value="18600" spread="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Piperaquine Cmax</title>
        <description>Piperaquine maximum concentration observed</description>
        <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
        <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
            <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine Cmax</title>
          <description>Piperaquine maximum concentration observed</description>
          <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202" spread="37.6"/>
                    <measurement group_id="O2" value="122" spread="42.1"/>
                    <measurement group_id="O3" value="630" spread="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Piperaquine AUC0-inf</title>
        <description>Area under the Piperaquine plasma concentration time curve from time zero to time infinity using observed values.</description>
        <time_frame>Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43</time_frame>
        <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
            <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
            <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
          </group>
        </group_list>
        <measure>
          <title>Piperaquine AUC0-inf</title>
          <description>Area under the Piperaquine plasma concentration time curve from time zero to time infinity using observed values.</description>
          <population>Pharmacokinetic parameters were evaluated using all available concentration data from all 24 subjects who had received at least one treatment of randomised study medication.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17200" spread="29.5"/>
                    <measurement group_id="O2" value="13400" spread="23.1"/>
                    <measurement group_id="O3" value="29700" spread="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 43 post-dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: PQP 1440mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: PQP 960mg &amp; OZ439+TPGS 800mg</title>
          <description>PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C - PQP 1440mg &amp; OZ439 PIB 800mg</title>
          <description>PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After completion of the study, the Investigator may prepare a joint publication with the Sponsor. The Investigator must undertake not to submit any part of the individual data from this protocol for publication without prior consent of the Sponsor at a mutually agreed time.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Thomas Rueckle</name_or_title>
      <organization>Medicines for Malaria Ventire (MMV)</organization>
      <phone>+41 22 799 4567</phone>
      <email>ruecklet@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

